Top in ID: FDA OKs updated COVID-19 vaccines; 1 in 3 men have genital HPV
The FDA approved updated COVID-19 vaccines last week that target omicron XBB subvariants of SARS-CoV-2, which have become the predominant SARS-CoV-2 viruses worldwide.
The monovalent messenger RNA vaccines from Moderna and Pfizer-BioNTech were fully approved for people aged 12 years and older and authorized for emergency use in children aged 6 months to 11 years.
It was the top story in infectious disease last week.
The second top story focused on a systematic review and meta-analysis that found nearly one-third of men have at least one type of genital HPV. According to the study, HPV is more prevalent among young men, with the highest prevalence among men aged 25 to 29 years.
Read these and more top stories in infectious disease below:
FDA approves updated COVID-19 vaccines
The FDA approved and authorized updated COVID-19 vaccines from Moderna and Pfizer-BioNTech that target omicron XBB subvariants of SARS-CoV-2. Read more.
Nearly one-third of men worldwide have genital HPV
Roughly one-third of men globally have at least one type of genital HPV and one in five are infected with at least one high-risk HPV type, according to the results of a systematic review and meta-analysis. Read more.
CDC recommends updated COVID-19 vaccines
The CDC recommended the updated monovalent COVID-19 vaccines for people aged older than 6 months. Read more.
Q&A: How can novel antibiotics help combat antimicrobial resistance?
At this year’s World Anti-Microbial Resistance Congress, Ricardo Chaves, MD, PhD, the executive medical director of clinical development at Debiopharm, moderated a panel on novel antibiotics. Read more.
‘Incorrect’ initial antibiotic treatment for K. pneumonia increases patient mortality
After assessing Klebsiella pneumoniae bloodstream infections, researchers are calling for more rapid identification methods to find patients with resistant infections because choosing the wrong first antibiotics increases mortality risk. Read more.